{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:25:08Z","timestamp":1792844708820,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T00:00:00Z","timestamp":1349913600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s13311-012-0150-9","type":"journal-article","created":{"date-parts":[[2012,10,10]],"date-time":"2012-10-10T19:31:43Z","timestamp":1349897503000},"page":"739-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes"],"prefix":"10.1016","volume":"9","author":[{"given":"Emmanuel J.M.","family":"Mignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-012-0150-9_bib1","unstructured":"American Psychiatric Association. DSM-5 Development. In: DSM-5: The Future of Psychiatric Diagnosis Available at: http:\/\/www.dsm5.org\/."},{"key":"10.1007\/s13311-012-0150-9_bib2","first-page":"207","article-title":"A hundred years of narcolepsy research","volume":"139","author":"Mignot","year":"2001","journal-title":"Arch Ital Biol"},{"key":"10.1007\/s13311-012-0150-9_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-012-0150-9_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12035-009-8053-4","article-title":"A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters","volume":"39","author":"Robertson","year":"2009","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-012-0150-9_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0306-4522(00)00239-6","article-title":"Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy","volume":"99","author":"Kanbayashi","year":"2000","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-012-0150-9_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-4159.2011.07335.x","article-title":"Dopamine release mediated by the dopamine transporter, facts and consequences","volume":"118","author":"Leviel","year":"2011","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-012-0150-9_bib7","doi-asserted-by":"crossref","first-page":"E847","DOI":"10.1208\/aapsj070481","article-title":"Role of monoamine transporters in mediating psychostimulant effects","volume":"7","author":"Riddle","year":"2005","journal-title":"AAPS J"},{"key":"10.1007\/s13311-012-0150-9_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/bc.2011.016","article-title":"The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d), methamphetamine and D-amphetamine","volume":"392","author":"Steinkellner","year":"2011","journal-title":"Biol Chem"},{"key":"10.1007\/s13311-012-0150-9_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/sleep\/14.3.218","article-title":"Relative efficacy of drugs for the treatment of sleepiness in narcolepsy","volume":"14","author":"Mitler","year":"1991","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2165\/00023210-200418140-00005","article-title":"New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential","volume":"18","author":"Connor","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-012-0150-9_bib11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1345\/aph.1L523","article-title":"An update on central nervous system stimulant formulations in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"43","author":"Chavez","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"10.1007\/s13311-012-0150-9_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2008.05.022","article-title":"Imaging dopamine's role in drug abuse and addiction","volume":"56","author":"Volkow","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-012-0150-9_bib13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-012-0150-9_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/11536380-000000000-00000","article-title":"Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder","volume":"33","author":"Stiefel","year":"2010","journal-title":"Drug Saf"},{"key":"10.1007\/s13311-012-0150-9_bib15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/sleep\/16.3.199a","article-title":"Amphetamines and narcolepsy: use of the Stanford database","volume":"16","author":"Guilleminault","year":"1993","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","article-title":"The pharmacology of selegiline","volume":"100","author":"Magyar","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1007\/s13311-012-0150-9_bib17","first-page":"620","article-title":"The treatment of narcolepsy with methyl phenylpiperidylacetate: a preliminary report","volume":"31","author":"Daly","year":"1956","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"10.1007\/s13311-012-0150-9_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-0348-8171-5_4","article-title":"The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate","volume":"59","author":"Schenk","year":"2002","journal-title":"Prog Drug Res"},{"key":"10.1007\/s13311-012-0150-9_bib20","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/JCP.0b013e3181733560","article-title":"Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?","volume":"28","author":"Markowitz","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0924-977X(02)00104-9","article-title":"Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies","volume":"12","author":"Volkow","year":"2002","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473710902020157","article-title":"Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences","volume":"2","author":"Bogle","year":"2009","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1007\/s13311-012-0150-9_bib23","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.49.2.444","article-title":"Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy","volume":"49","author":"Broughton","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-012-0150-9_bib24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1212\/WNL.54.5.1166","article-title":"Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy","volume":"54","author":"US Modafinil in Narcolepsy Multicenter Study Group","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-012-0150-9_bib25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0025-6196(11)60666-6","article-title":"Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study","volume":"84","author":"Czeisler","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s13311-012-0150-9_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5664\/jcsm.27934","article-title":"Tolerability and efficacy of armodafinil in naive patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period","volume":"6","author":"Schwartz","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-2999(90)90591-S","article-title":"Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals","volume":"180","author":"Duteil","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/10401230490453743","article-title":"Modafinil: preclinical, clinical, and post-marketing surveillance\u2013a review of abuse liability issues","volume":"16","author":"Myrick","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"10.1007\/s13311-012-0150-9_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF02244337","article-title":"Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers","volume":"113","author":"Mignot","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-012-0150-9_bib30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/sleep\/17.5.436","article-title":"Modafinil binds to the dopamine uptake carrier site with low affinity","volume":"17","author":"Mignot","year":"1994","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib31","first-page":"49","article-title":"Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants","volume":"1","author":"Nishino","year":"1998","journal-title":"Sleep Res Online"},{"key":"10.1007\/s13311-012-0150-9_bib32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.2009.351","article-title":"Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications","volume":"301","author":"Volkow","year":"2009","journal-title":"JAMA"},{"key":"10.1007\/s13311-012-0150-9_bib33","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2010.08.026","article-title":"A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [(1)(1)C]altropane and [(1)(1)C]raclopride","volume":"68","author":"Spencer","year":"2010","journal-title":"Biological psychiatry"},{"key":"10.1007\/s13311-012-0150-9_bib34","doi-asserted-by":"crossref","first-page":"e25790","DOI":"10.1371\/journal.pone.0025790","article-title":"The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors","volume":"6","author":"Schmitt","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-012-0150-9_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11315280-000000000-00000","article-title":"Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies","volume":"29","author":"Darwish","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-012-0150-9_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/0044011-200929020-00003","article-title":"Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies","volume":"29","author":"Darwish","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1007\/s13311-012-0150-9_bib37","first-page":"293","article-title":"A review of modafinil film-coated tablets for attention-deficit\/hyperactivity disorder in children and adolescents","volume":"3","author":"Rugino","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1007\/s13311-012-0150-9_bib38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa041292","article-title":"Modafinil for excessive sleepiness associated with shift-work sleep disorder","volume":"353","author":"Czeisler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-012-0150-9_bib39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/ajrccm.163.4.2005036","article-title":"Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea\/hypopnea syndrome","volume":"163","author":"Kingshott","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1007\/s13311-012-0150-9_bib40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/sleep\/28.9.1189","article-title":"Atomoxetine also effective in patients suffering from narcolepsy?","volume":"28","author":"Niederhofer","year":"2005","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib41","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/sleep\/28.6.754","article-title":"Emerging therapies in narcolepsy-cataplexy","volume":"28","author":"Mignot","year":"2005","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib42","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2008.036","article-title":"Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations","volume":"19","author":"Moller","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.sleep.2008.06.004","article-title":"Rebound cataplexy after withdrawal from antidepressants","volume":"10","author":"Broderick","year":"2009","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0317167100119304","article-title":"The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate","volume":"6","author":"Broughton","year":"1979","journal-title":"Can J Neurol Sci"},{"key":"10.1007\/s13311-012-0150-9_bib46","first-page":"42","article-title":"A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy","volume":"25","author":"Xyrem","year":"2002","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib47","first-page":"31","article-title":"A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy","volume":"26","author":"Xyrem","year":"2003","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib48","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5664\/jcsm.27994","article-title":"The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy","volume":"6","author":"Black","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","article-title":"Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy","volume":"5","author":"Xyrem","year":"2004","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/sleep\/21.5.507","article-title":"Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients","volume":"21","author":"Scharf","year":"1998","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-008-1160-5","article-title":"Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonists","volume":"199","author":"Koek","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-012-0150-9_bib53","doi-asserted-by":"crossref","first-page":"14194","DOI":"10.1523\/JNEUROSCI.3145-10.2010","article-title":"Differential effects of GABAB receptor subtypes, {gamma}-hydroxybutyric Acid, and Baclofen on EEG activity and sleep regulation","volume":"30","author":"Vienne","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-012-0150-9_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pediatrneurol.2009.02.008","article-title":"Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate","volume":"41","author":"Huang","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-012-0150-9_bib55","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/sleep\/27.7.1242","article-title":"Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy","volume":"27","author":"Arnulf","year":"2004","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/sleep\/33.9.1217","article-title":"Enhancing slow wave sleep with sodium oxybate reduces the behavioral and physiological impact of sleep loss","volume":"33","author":"Walsh","year":"2010","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib57","first-page":"2619","article-title":"Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine","volume":"69","author":"Gahlinger","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1007\/s13311-012-0150-9_bib58","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.genhosppsych.2008.11.001","article-title":"Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known","volume":"31","author":"van Noorden","year":"2009","journal-title":"Gen Hosp Psychiatr"},{"key":"10.1007\/s13311-012-0150-9_bib59","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1081\/CLT-120019128","article-title":"The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms","volume":"41","author":"Xyrem","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1007\/s13311-012-0150-9_bib60","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","article-title":"Weight loss in narcolepsy patients treated with sodium oxybate","volume":"10","author":"Husain","year":"2009","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5664\/JCSM.1082","article-title":"Sodium oxybate-induced sleep driving and sleep-related eating disorder","volume":"7","author":"Wallace","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib62","article-title":"Catathrenia under sodium oxybate in narcolepsy with cataplexy","author":"Poli","year":"2011","journal-title":"Sleep Breath"},{"key":"10.1007\/s13311-012-0150-9_bib63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sleep.2009.06.006","article-title":"A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing","volume":"11","author":"George","year":"2010","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11325-009-0320-0","article-title":"A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome","volume":"15","author":"George","year":"2011","journal-title":"Sleep Breath"},{"key":"10.1007\/s13311-012-0150-9_bib65","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.sleep.2007.11.018","article-title":"Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports","volume":"10","author":"Seeck-Hirschner","year":"2009","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib66","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.sleep.2009.02.002","article-title":"Xyrem safety: the debate continues","volume":"10","author":"Feldman","year":"2009","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5664\/JCSM.1216","article-title":"Sodium oxybate post-marketing surveillance","volume":"7","author":"Feldman","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5664\/JCSM.1214","article-title":"Sodium oxybate: updates and correction to previously published safety data","volume":"7","author":"Wang","year":"2011","journal-title":"J Clin Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.sleep.2009.09.001","article-title":"Use of sodium oxybate (Xyrem in patients with dual diagnosis of narcolepsy and sleep apnea","volume":"11","author":"Kovacevic-Ristanovic","year":"2010","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.pain.2010.12.022","article-title":"Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study","volume":"152","author":"Russell","year":"2011","journal-title":"Pain"},{"key":"10.1007\/s13311-012-0150-9_bib71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ana.21333","article-title":"Kleine-Levin syndrome: a systematic study of 108 patients","volume":"63","author":"Arnulf","year":"2008","journal-title":"Ann Neurolp"},{"key":"10.1007\/s13311-012-0150-9_bib72","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1093\/brain\/awh620","article-title":"Kleine-Levin syndrome: a systematic review of 186 cases in the literature","volume":"128","author":"Arnulf","year":"2005","journal-title":"Brain"},{"key":"10.1007\/s13311-012-0150-9_bib73","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(12)70187-4","article-title":"Diagnosis, disease course, and management of patients with Kleine-Levin syndrome","volume":"11","author":"Arnulf","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-012-0150-9_bib74","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/sleep\/29.7.890","article-title":"The prevalence of multiple sleep-onset REM periods in a population-based sample","volume":"29","author":"Singh","year":"2006","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib75","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awl079","article-title":"Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults","volume":"129","author":"Mignot","year":"2006","journal-title":"Brain"},{"key":"10.1007\/s13311-012-0150-9_bib76","first-page":"S23","article-title":"Endogenous GABA(A) Receptor Enhancement Modulates Vigilance in the Primary Hypersomnias","volume":"70","author":"Rye","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-012-0150-9_bib77","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.chc.2007.11.010","article-title":"Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function","volume":"17","author":"Vitiello","year":"2008","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1007\/s13311-012-0150-9_bib78","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/sleep\/33.11.1457","article-title":"Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children","volume":"33","author":"Aran","year":"2010","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.sleep.2010.02.017","article-title":"Clinical, polysomnographic and laboratory characteristics of narcolepsy-cataplexy in a sample of children and adolescents","volume":"12","author":"Peraita-Adrados","year":"2011","journal-title":"Sleep Med"},{"key":"10.1007\/s13311-012-0150-9_bib80","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5665\/sleep.1836","article-title":"Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study","volume":"35","author":"Lecendreux","year":"2012","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ana.22587","article-title":"Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China","volume":"70","author":"Han","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-012-0150-9_bib82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-0030-1267993","article-title":"Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy","volume":"41","author":"Knudsen","year":"2010","journal-title":"Neuropediatrics"},{"key":"10.1007\/s13311-012-0150-9_bib83","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ng.372","article-title":"Narcolepsy is strongly associated with the T-cell receptor alpha locus","volume":"41","author":"Hallmayer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-012-0150-9_bib84","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","article-title":"Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog","volume":"26","author":"Fujiki","year":"2003","journal-title":"Sleep"},{"key":"10.1007\/s13311-012-0150-9_bib85","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-012-0150-9_bib86","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0269881112448946","article-title":"Orexin receptor antagonism: an ascending multiple-dose study with almorexant","volume":"26","author":"Hoever","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib87","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/156802608784936728","article-title":"Histamine H3 antagonists as wake-promoting and pro-cognitive agents","volume":"8","author":"Stocking","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1007\/s13311-012-0150-9_bib88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/WNF.0b013e318246879d","article-title":"Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness","volume":"35","author":"Inocente","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-012-0150-9_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2011.1240","article-title":"Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology","volume":"69","author":"Ohayon","year":"2012","journal-title":"Arch Gen Psychiatry"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923017166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923017166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s13311-012-0150-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:09:47Z","timestamp":1761808187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923017166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1878747923017166"],"URL":"https:\/\/doi.org\/10.1007\/s13311-012-0150-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-012-0150-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}